Eli Lilly and Company (LLY)vsSTAAR Surgical Company (STAA)
LLY
Eli Lilly and Company
$1,102.08
+0.45%
HEALTHCARE · Cap: $1.01T
STAA
STAAR Surgical Company
$28.83
+0.44%
HEALTHCARE · Cap: $1.41B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 24781% more annual revenue ($72.25B vs $290.38M). LLY leads profitability with a 35.0% profit margin vs -7.2%. STAA appears more attractively valued with a PEG of 0.76. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
STAA
Hold47
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+44.9%
Fair Value
$31.32
Current Price
$28.83
$2.49 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Revenue surging 119.6% year-over-year
Conservative balance sheet, low leverage
Growing faster than its price suggests
Areas to Watch
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 31.6x book value
Grey zone — moderate risk
Smaller company, higher risk/reward
Weak financial health signals
ROE of -6.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : STAA
The strongest argument for STAA centers on Revenue Growth, Debt/Equity, PEG Ratio. Revenue growth of 119.6% demonstrates continued momentum. PEG of 0.76 suggests the stock is reasonably priced for its growth.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 40.2x leaves little room for execution misses.
Bear Case : STAA
The primary concerns for STAA are Altman Z-Score, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
LLY profiles as a growth stock while STAA is a hypergrowth play — different risk/reward profiles.
STAA carries more volatility with a beta of 1.23 — expect wider price swings.
STAA is growing revenue faster at 119.6% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 47/100), backed by strong 35.0% margins and 55.5% revenue growth. STAA offers better value entry with a 44.9% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →STAAR Surgical Company
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
STAAR Surgical Company designs, develops, manufactures, markets and sells implantable eye lenses and supplemental delivery systems for placing the lenses in the eye. The company is headquartered in Lake Forest, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?